12:00 AM
 | 
Dec 24, 2012
 |  BC Week In Review  |  Company News  |  Deals

Vivacta, Novartis deal

Novartis acquired diagnostic company Vivacta for $90 million. Vivacta could not be reached for comment while Novartis said the deal provides it with access to Vivacta's platform to develop point-of-care diagnostic tests to improve therapeutic drug monitoring. The pharma will initially focus on transplant patients taking the immunosuppressant indications of everolimus.

Vivacta Ltd., Sittingbourne,...

Read the full 255 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >